Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6518274 | 0.86 | EED (0.36) | TAAR1KDM4EPOLBGAALMNA | |
| SCHEMBL2199784 | 0.86 | TAAR1 (0.63) | TAAR1KDM4EGAADAOSMN1; SMN2 | |
| SCHEMBL249134 | 0.85 | TAAR1 (0.45) | TAAR1KDM4EPOLBGAADAO | |
| SCHEMBL6284488 | 0.82 | STIM1 (0.39) | TAAR1KDM4EPOLBSMN1; SMN2 | |
| SCHEMBL6514684 | 0.82 | KDM4E (0.37) | TAAR1KDM4EPOLBGAALMNA | |
| SCHEMBL7701701 | 0.79 | TAAR1 (0.52) | TAAR1KDM4EPOLBGAADAO | |
| SCHEMBL5734084 | 0.78 | TAAR1 (0.54) | TAAR1GAADAO | |
| SCHEMBL14671415 | 0.76 | SMN1; SMN2 (0.46) | TAAR1KDM4EGAADAOHPGD | |
| SCHEMBL6130256 | 0.76 | TAAR1 (0.42) | TAAR1KDM4EPOLBGAADAO | |
| SCHEMBL2554030 | 0.76 | TAAR1 (0.42) | TAAR1KDM4EPOLBGAADAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2555623-A1 | FLAVIN DERIVATIVES | BioRelix, Inc. (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20130029980-A1 | FLAVIN DERIVATIVES | COISH PHILIP D G (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029980-A1 | FLAVIN DERIVATIVES | COISH PHILIP D G (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029980-A1 | FLAVIN DERIVATIVES | COISH PHILIP D G (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2011126567-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011126567-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| EP-1311471-B1 | PHENYL- AND PHENYLALKYL-SUBSTITUTED ETHANOLAMINES AND ETHYLENEDIAMINES | BOEHRINGER INGELHEIM PHARMA (DE) | 2006-04-12 | — | — | EP | disclosed |
| US-6770636-B2 | CENTRAL NERVOUS SYSTEM DISORDERS THERAPY | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-08-03 | — | — | US | disclosed |
| EP-1311471-A1 | PHENYL- AND PHENYLALKYL-SUBSTITUTED ETHANOLAMINES AND ETHYLENEDIAMINES | Boehringer Ingelheim Pharma KG (DE) | 2003-05-21 | — | — | EP | disclosed |
| US-20020042410-A1 | Phenyl-and phenylalkyl-substituted ethanolamines and ethylenediamines | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-11 | — | — | US | disclosed |
| WO-2002016308-A1 | PHENYL- AND PHENYLALKYL-SUBSTITUTED ETHANOLAMINES AND ETHYLENEDIAMINES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029980-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | TAAR1 3574/4885KDM4E 2353/4885POLB 1215/4885 |
| US-20020042410-A1 | Phenyl-and phenylalkyl-substituted ethanolamines and ethylenediamines | AOC2, CYC1, CYCS | TAAR1 245/4885KDM4E 3017/4885POLB 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.